Welcome to our dedicated page for Illumina news (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.
Illumina develops DNA sequencing, array-based, informatics and proteomics technologies for research, clinical and applied markets. Company news commonly covers sequencing instruments and consumables, NovaSeq X demand, DRAGEN software releases, TruPath Genome analytical support, and applications in oncology, reproductive health, agriculture, rare disease and drug discovery.
Illumina updates also include collaborations around precision oncology testing, preventive and population genomics, pediatric cancer and rare disease data, and the Alliance for Genomic Discovery. Financial and corporate news covers revenue trends, operating margins, earnings guidance, share repurchase authorizations, acquisitions in multiomics and proteomics, and board or management changes.
Illumina reported financial results for Q1 2024, with core revenue at $1.06 billion, a 2% decrease from Q1 2023. GAAP operating margin was 11.0% and non-GAAP operating margin was 20.6%. Revenue decreased by 1% to $1.08 billion. GAAP diluted loss per share was ($0.79), while non-GAAP diluted earnings per share were $0.09. Illumina aims to divest GRAIL by end of Q2 2024, with a funding commitment of $1 billion in a capital markets transaction.
In celebration of DNA Day, Illumina in Cambridge, United Kingdom, hosted 150 students for hands-on science activities, inspiring young scientists to pursue careers in STEM. HRH The Princess Royal visited the event, emphasizing the importance of genomics and STEM education. The Future Is Bright initiative, promoting global genomic literacy, engages 100,000 learners annually, aiming to reach 5 million by 2030.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.